{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-24-000147","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.454388+00:00","generated_at":"2026-05-31T12:21:54.422074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment","bullets":["Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.","R&D expenses $75.5M, up 49% YoY, driven by IMVT-1402 prep and batoclimab trials.","Completed enrollment in batoclimab pivotal MG trial; top-line results expected by March 31, 2025.","Plans to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025; 3 IND applications active by end-2024.","Graves' disease program update expected fall 2024; batoclimab TED top-line data in H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-24-000147","json":"https://secwatch.observer/filing/0001764013-24-000147.json","markdown":"https://secwatch.observer/filing/0001764013-24-000147.md","text":"https://secwatch.observer/filing/0001764013-24-000147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000147/0001764013-24-000147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000147/imvt-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:21:54.422074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}